RYTM
VENTE TOTALE: 50 000 titres (~5 087 320,00 $ US)
- Insiders
- Meeker David P
- Total bought
- —
- Total sold
- $5,087,320
- Last activity
- 2026-09-14
- Last synced
-
2026-09-16 10:16:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signal Scored 2026-09-16
RYTM combines a weak catalyst score (25, NONE-type) driven by a significant insider sale that overshadowed the Japan MHLW approval, with fragile fundamentals marked by heavy cash burn, negative ROIC, and extreme…
The first sentence of the analysis written for RYTM on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | |
| Ebit Margin | -92.5% | -184.2% | -219.8% | -744.2% | -2207.1% | |
| Ebitda Margin | -91.8% | -183.0% | -217.6% | -737.1% | -2170.4% | |
| Operating Profit Margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | |
| Pretax Profit Margin | -103.3% | -200.0% | -237.8% | -766.2% | -2207.1% | |
| Continuous Operations Profit Margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | |
| Net Profit Margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | |
| Bottom Line Profit Margin | -106.4% | -203.3% | -238.5% | -766.2% | -2207.1% | |
| Current Ratio | 4.407 | 3.239 | 5.584 | 8.898 | 7.101 | |
| Quick Ratio | 4.164 | 3.077 | 5.428 | 8.825 | 7.099 | |
| Solvency Ratio | -0.929 | -1.138 | -1.122 | -1.518 | -1.509 | |
| Cash Ratio | 0.513 | 0.772 | 1.088 | 3.207 | 1.364 | |
| Price To Earnings Ratio | -34.418 | -12.899 | -14.366 | -8.296 | -7.285 | |
| Price To Earnings Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Forward Price To Earnings Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Price To Earnings Diluted Ratio | -34.418 | -12.899 | -14.366 | -8.296 | -7.285 | |
| Price To Earnings Diluted Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Price To Book Ratio | 25.760 | 20.751 | 15.618 | 5.743 | 1.742 | |
| Price To Sales Ratio | 36.657 | 26.240 | 34.241 | 64.208 | 156.947 | |
| Price To Free Cash Flow Ratio | -59.642 | -29.984 | -19.465 | -8.541 | -3.269 | |
| Price To Operating Cash Flow Ratio | -60.133 | -29.984 | -19.472 | -8.751 | -3.390 | |
| Debt To Assets Ratio | 0.008 | 0.010 | 0.004 | 0.005 | 0.008 | |
| Debt To Equity Ratio | 0.015 | 0.024 | 0.007 | 0.007 | 0.009 | |
| Debt To Capital Ratio | 0.015 | 0.023 | 0.007 | 0.007 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.778 | 2.384 | 1.960 | 1.447 | 1.160 | |
| Working Capital Turnover Ratio | 0.612 | 0.509 | 0.273 | 0.082 | 0.015 | |
| Operating Cash Flow Ratio | -1.092 | -0.986 | -2.466 | -4.357 | -3.362 | |
| Operating Cash Flow Sales Ratio | -0.610 | -0.875 | -1.758 | -7.337 | -46.291 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | 1.000 | 1.000 | 1.025 | 1.037 | |
| Debt Service Coverage Ratio | -8.484 | -11.573 | -12.167 | -33.502 | 0.000 | |
| Interest Coverage Ratio | -9.329 | -12.887 | -13.271 | -34.447 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -28.977 | -28.918 | -108.061 | -89.212 | -57.234 | |
| Capital Expenditure Coverage Ratio | -121.380 | 0.000 | -2,896.957 | -40.511 | -26.868 | |
| Dividend Paid And Capex Coverage Ratio | -121.380 | -28.685 | -2,896.957 | -40.511 | -26.868 | |
| Dividend Payout Ratio | 0.000 | -0.015 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -39.660 | -13.983 | -15.389 | -7.989 | -6.403 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 89.7% | 0.0% | ▲1.8% |
| Ebit Margin | -92.5% | ▲91.7% | ▲597.1% |
| Ebitda Margin | -91.8% | ▲91.2% | ▲588.2% |
| Operating Profit Margin | -101.2% | ▲102.8% | ▲1237.4% |
| Pretax Profit Margin | -103.3% | ▲96.7% | ▲599.6% |
| Continuous Operations Profit Margin | -103.6% | ▲96.7% | ▲599.6% |
| Net Profit Margin | -103.6% | ▲96.7% | ▲599.6% |
| Bottom Line Profit Margin | -106.4% | ▲96.9% | ▲597.9% |
| Current Ratio | 4.407 | ▲1.168 | ▼-1.439 |
| Quick Ratio | 4.164 | ▲1.087 | ▼-1.554 |
| Solvency Ratio | -0.929 | ▲0.209 | ▲0.314 |
| Cash Ratio | 0.513 | ▼-0.259 | ▼-0.876 |
| Price To Earnings Ratio | -34.418 | ▼-21.519 | ▼-18.965 |
| Price To Earnings Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Forward Price To Earnings Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Price To Earnings Diluted Ratio | -34.418 | ▼-21.519 | ▼-18.965 |
| Price To Earnings Diluted Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Price To Book Ratio | 25.760 | ▲5.010 | ▲11.837 |
| Price To Sales Ratio | 36.657 | ▲10.417 | ▼-27.002 |
| Price To Free Cash Flow Ratio | -59.642 | ▼-29.658 | ▼-35.462 |
| Price To Operating Cash Flow Ratio | -60.133 | ▼-30.150 | ▼-35.787 |
| Debt To Assets Ratio | 0.008 | ▼-0.002 | ▲0.001 |
| Debt To Equity Ratio | 0.015 | ▼-0.009 | ▲0.002 |
| Debt To Capital Ratio | 0.015 | ▼-0.009 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.778 | ▼-0.606 | ▲0.033 |
| Working Capital Turnover Ratio | 0.613 | ▲0.104 | ▲0.314 |
| Operating Cash Flow Ratio | -1.092 | ▼-0.106 | ▲1.361 |
| Operating Cash Flow Sales Ratio | -0.610 | ▲0.266 | ▲10.765 |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | ▲0.008 | ▼-0.006 |
| Debt Service Coverage Ratio | -8.484 | ▲3.089 | ▲4.662 |
| Interest Coverage Ratio | -9.329 | ▲3.558 | ▲4.658 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -28.977 | ▼-0.059 | ▲33.504 |
| Capital Expenditure Coverage Ratio | -121.380 | ▼-121.380 | ▲495.764 |
| Dividend Paid And Capex Coverage Ratio | -121.380 | ▼-92.695 | ▲501.500 |
| Dividend Payout Ratio | 0.000 | ▲0.015 | ▲0.003 |
| Enterprise Value Multiple | -39.660 | ▼-25.677 | ▼-22.975 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.96B | $3.41B | $2.65B | $1.52B | $495.0M | |
| Enterprise value | $6.91B | $3.33B | $2.59B | $1.39B | $438.3M | |
| EV / Sales | 36.39x | 25.59x | 33.48x | 58.89x | 138.97x | |
| EV / Op. cash flow | -59.70x | -29.23x | -19.04x | -8.03x | -3.00x | |
| EV / Free cash flow | -59.21x | -29.23x | -19.03x | -7.83x | -2.89x | |
| EV / EBITDA | -39.66x | -13.98x | -15.39x | -7.99x | -6.40x | |
| Net debt / EBITDA | 0.29x | 0.36x | 0.35x | 0.72x | 0.83x | |
| Current ratio | 4.41x | 3.24x | 5.58x | 8.90x | 7.10x | |
| Income quality | 0.59x | 0.44x | 0.74x | 0.96x | 2.10x | |
| Graham net-net | $3 | $2 | $2 | $4 | $5 | |
| Tax burden | 100.3% | 100.1% | 100.3% | 100.0% | 100.0% | |
| Interest burden | 111.7% | 108.6% | 108.2% | 103.0% | 100.0% | |
| Working capital | $361.0M | $258.7M | $253.1M | $314.4M | $265.0M | |
| Invested capital | $370.4M | $269.0M | $262.2M | $325.7M | $274.0M | |
| Return on assets | -40.9% | -66.4% | -55.5% | -47.4% | -21.1% | |
| Operating ROA | -44.0% | -73.2% | -51.6% | -50.3% | -65.8% | |
| Return on tangible assets | -41.4% | -67.5% | -56.7% | -48.4% | -21.4% | |
| Return on equity | -72.8% | -158.4% | -108.8% | -68.5% | -24.5% | |
| Return on invested capital | -51.2% | -95.9% | -66.2% | -52.2% | -59.3% | |
| Return on capital employed | -51.3% | -95.9% | -66.4% | -52.3% | -59.4% | |
| Earnings yield | -2.8% | -7.6% | -7.0% | -11.9% | -14.1% | |
| Free cash flow yield | -1.7% | -3.3% | -5.1% | -11.7% | -30.6% | |
| Capex / Op. cash flow | -0.8% | 0.0% | -0.0% | -2.5% | -3.7% | |
| Capex / Depreciation | 71.2% | 0.0% | 2.7% | 256.0% | 469.3% | |
| Capex / Sales | 0.5% | 0.0% | 0.1% | 18.1% | 172.3% | |
| SG&A / Sales | 102.7% | 110.9% | 151.8% | 389.3% | 2171.4% | |
| R&D / Sales | 88.2% | 182.9% | 174.3% | 459.6% | 3301.5% | |
| Stock comp / Sales | 35.2% | 30.5% | 42.0% | 83.9% | 659.6% | |
| Intangibles / Total assets | 1.1% | 1.6% | 2.1% | 2.1% | 1.4% | |
| Days sales outstanding | 50d | 52d | 70d | 96d | 119d | |
| Days payables outstanding | 261d | 337d | 192d | 821d | 3496d | |
| Operating cycle | 532d | 564d | 408d | 595d | 186d | |
| Cash conversion cycle | 271d | 227d | 217d | -226d | -3310d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+103.7%EV / Sales ▲+42.2%EV / EBITDA ▼-183.6%EV / Op. cash flow ▼-30.463Earnings yield ▲+0.048
Profitability
Return on equity ▲+0.856Return on assets ▲+0.255Return on invested capital ▲+0.447Return on capital employed ▲+0.446Operating ROA ▲+0.292Income quality ▲+0.152Tax burden ▲+0.001
Efficiency
Days sales outstanding ▼-1.759Days payables outstanding ▼-75.437Operating cycle ▼-31.222Cash conversion cycle ▲+44.216Capex / Sales n/aR&D / Sales ▼-0.947
Balance-sheet strength
Current ratio ▲+1.168Net debt / EBITDA ▼-0.069Working capital ▲+102291000.000Invested capital ▲+101480000.000Intangibles / Total assets ▼-0.005
Change over 5 years
Valuation
Market cap ▲+1305.2%EV / Sales ▼-73.8%EV / EBITDA ▼-519.4%EV / Op. cash flow ▼-56.696Earnings yield ▲+0.112
Profitability
Return on equity ▼-0.483Return on assets ▼-0.198Return on invested capital ▲+0.081Return on capital employed ▲+0.081Operating ROA ▲+0.218Income quality ▼-1.509Tax burden ▲+0.003
Efficiency
Days sales outstanding ▼-68.452Days payables outstanding ▼-3234.668Operating cycle ▲+346.151Cash conversion cycle ▲+3580.820Capex / Sales ▼-1.718R&D / Sales ▼-32.133
Balance-sheet strength
Current ratio ▼-2.694Net debt / EBITDA ▼-0.539Working capital ▲+96014000.000Invested capital ▲+96493000.000Intangibles / Total assets ▼-0.003
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-16 Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and last traded at $97.0350. Approximately 54,752 shares traded hands during trading, a decline of 93% from the average session volume of 750,485 shares.
- 2026-09-15 Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting -- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company''s work in rare melanocortin-4 receptor (MC4R) pathway diseases at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting taking place September 8-10 in Marseille, France.
- 2026-08-28 Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solutions, Evolution Petroleum, Petrobras, Rythm Pharmaceuticals, Terawulf, UMB Financial, Workday, and More NVIDIA''s blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.
- 2026-08-28 Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 394,044 shares of the company''s stock, valued at approximately $43,751,000. Bank of New York Mellon Corp owned
- 2026-08-26 Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here''s What His New Positions Reveal Duquesne Family Office has beefed up its healthcare holdings.
- 2026-08-24 Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
- 2026-08-23 Eli Lilly and Novo Nordisk Can''t Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
- 2026-08-18 Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE''s AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM''s pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.
- 2026-08-17 Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.